Pediatric HIV/AIDS Cohort Study (PHACS) (U19 Clinical Trial Not Allowed)
ID: 356108Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $6M

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the Pediatric HIV/AIDS Cohort Study (PHACS) under the funding opportunity number RFA-HD-25-003. This initiative aims to investigate the developmental and clinical trajectories of youth living with perinatally acquired HIV, focusing on health outcomes, reproductive health, and the long-term effects of antiretroviral therapy (ART). The program is designed to enhance scientific knowledge in HIV-related health, particularly among underrepresented populations, while promoting collaboration and data sharing among multidisciplinary teams. Approximately $11 million is anticipated for one to two awards over five years, with applications due by December 11, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-25-003.html.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services is issuing a Notice of Funding Opportunity (NOFO) for the Pediatric HIV/AIDS Cohort Study (PHACS) under the funding opportunity number RFA-HD-25-003. This program focuses on understanding the developmental and clinical trajectories of youth living with perinatally acquired HIV in the United States. Key objectives include assessing the impacts of HIV and its treatment on health outcomes, reproductive health, and the generational consequences of long-term antiretroviral therapy (ART). The initiative encourages the integration of diverse perspectives and proposes a comprehensive Plan for Enhancing Diverse Perspectives (PEDP). Funding anticipated is approximately $11 million for one to two awards over five years, with application deadlines beginning November 11, 2024. Eligible organizations include higher education institutions, nonprofits, and government entities. The application submission process entails strict adherence to multi-project guidelines and requires a robust approach to data management, sharing, and collaboration among multidisciplinary teams. The program aims to enhance scientific knowledge in HIV-related health, particularly among underrepresented populations, while sustaining research infrastructure and sharing valuable data to inform future HIV treatment and prevention strategies.
    Similar Opportunities
    Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)" aimed at investigating the interactions between HIV, antiretroviral therapy (ART), and substance use during pregnancy. This initiative seeks to enhance understanding of placental health and its implications for maternal and fetal outcomes, particularly focusing on the pathophysiology of placental abnormalities in the context of substance misuse. The NIH plans to allocate up to $2 million for fiscal year 2025 to support 2-5 research project grants, with applications opening on October 15, 2024, and a submission deadline of November 15, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Preclinical Models of NeuroHIV in the cART Era" (Funding Opportunity Number: RFA-NS-24-035) aimed at developing innovative small animal models and human cellular systems that accurately reflect the interactions between the central nervous system (CNS) and the immune system in individuals living with HIV. This initiative seeks applications that propose the development and early-stage validation of next-generation humanized models to address cognitive and neurological impairments associated with chronic HIV infection, particularly in the context of antiretroviral therapy (ART). The total funding available for this initiative is approximately $6 million, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive methods for HIV and associated complications. The primary objective of this grant is to facilitate the planning activities necessary for submitting an Investigational New Drug (IND) application to the FDA, with a focus on translating innovative research into effective drug products. This funding opportunity is particularly significant as it encourages collaboration among multidisciplinary teams to address critical health challenges related to HIV. Interested applicants can apply starting February 13, 2024, with a total funding amount of $1,000,000 anticipated for 2-3 awards in fiscal year 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-029.html.
    Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS)," aimed at supporting multidisciplinary research teams investigating HIV pathogenesis and its associated comorbidities. The initiative seeks to foster collaboration among experts in HIV science, pathobiology, metabolism, and related fields to explore critical health issues such as gastrointestinal health, liver diseases, kidney function, and obesity in the context of HIV. With a total funding allocation of $2 million for 2-3 anticipated awards, applicants can request up to $500,000 per year for a maximum of five years, with proposals due by November 21, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details.
    Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Multidisciplinary Studies of HIV/AIDS and Aging," inviting applications for research that explores the intersection of HIV and aging. The primary objectives of this grant are to enhance understanding of the biological, clinical, and socio-behavioral aspects of aging in individuals living with HIV, as well as to improve strategies for testing, preventing, and treating HIV and managing related health complications. This funding opportunity is significant for advancing health interventions for older adults affected by HIV, with eligible applicants including a wide range of institutions such as higher education entities, community organizations, and tribal governments. Interested parties should note that the application deadline is May 7, 2027, and can find further details and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-091.html.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research to enhance the integration of HIV, addiction, and primary care services. This initiative invites applications for R34 Planning Grants to develop and test models that improve healthcare delivery for individuals at risk for or living with HIV, Hepatitis B and C, and substance use disorders, with a focus on strategies such as integrating substance misuse prevention within HIV care settings. The total funding available for this project is $2 million, with awards potentially lasting up to three years, and applications are due by March 20, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)." This initiative aims to identify innovative cure strategies that can be implemented at the onset of combination antiretroviral therapy (cART) or upon restarting cART after an analytical treatment interruption, with the ultimate goal of achieving sustained treatment-free remission. The NIH encourages multidisciplinary research approaches that enhance understanding of HIV dynamics and improve strategies for sustained remission, while excluding clinical trials. Interested applicants, including a diverse range of institutions such as historically black colleges, tribal governments, and community-based organizations, must submit their proposals by September 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-297.html.
    Cellular Models of HIV Pathogenesis within NIDDK Mission Areas (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has announced a funding opportunity for research focused on developing cellular models of HIV pathogenesis. This initiative aims to enhance understanding of HIV interactions with human tissues by utilizing innovative three-dimensional models, such as organoids and microphysiological systems, to investigate mechanisms of viral persistence and associated co-occurring conditions. The funding opportunity allows for a budget of up to $500,000 annually, with a total commitment of $3 million for the fiscal year 2026, and applications are due by March 20, 2025. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-021.html.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.